See more : GSN Corporations Limited (8242.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Achieve Life Sciences, Inc. (ACHV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Achieve Life Sciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Natura &Co Holding S.A. (NTCO3.SA) Income Statement Analysis – Financial Results
- Ocular Therapeutix, Inc. (OCUL) Income Statement Analysis – Financial Results
- TriCo Bancshares (TCBK) Income Statement Analysis – Financial Results
- Wolford Aktiengesellschaft (WOL.VI) Income Statement Analysis – Financial Results
- NPC Co., Ltd. (004255.KS) Income Statement Analysis – Financial Results
Achieve Life Sciences, Inc. (ACHV)
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 8.75M | 408.41K | 12.10M | 5.10M | 18.90M | 16.60M | 4.50M | 1.10M |
| Cost of Revenue | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.22M | 3.69M | -600.00K | -800.00K | -600.00K | -500.00K | -300.00K | 5.50M |
| Gross Profit | -228.00K | -236.00K | -250.00K | -255.00K | -254.00K | -282.00K | -282.00K | 5.06M | 18.16M | 27.12M | 29.88M | 20.10M | 5.50M | 13.62M | 25.54M | 20.13M | 20.13M | 22.39M | 8.25M | 264.96M | 25.00K | 25.00K | 3.53M | -3.28M | 12.70M | 5.90M | 19.50M | 17.10M | 4.80M | -4.40M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 40.33% | -803.51% | 104.96% | 115.69% | 103.17% | 103.01% | 106.67% | -400.00% |
| Research & Development | 15.81M | 30.08M | 23.97M | 6.88M | 9.67M | 5.87M | 3.10M | 14.79M | 25.11M | 46.22M | 55.32M | 39.95M | 21.55M | 18.48M | 24.16M | 7.82M | 27.15M | 41.10M | 24.49M | 10.71M | 7.65M | 8.96M | 5.22M | 3.26M | 5.60M | 10.50M | 11.60M | 11.20M | 7.20M | 0.00 |
| General & Administrative | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 0.00 | 5.84M | 3.96M | 3.29M | 8.22B | 7.58B | 5.57B | 5.87B | 3.01B | 3.24B | 3.31M | 3.95M | 5.78M | 6.55M | 7.20M | 3.81M | 2.20M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -8.21B | -7.57B | -5.56B | -5.86B | -3.01B | -3.24B | 888.00 | 432.52K | 720.00K | -50.00K | 0.00 | -10.00K | 0.00 | 0.00 |
| SG&A | 11.44M | 10.72M | 9.13M | 7.87M | 6.85M | 6.95M | 3.53M | 8.93M | 11.81M | 10.63M | 9.89M | 7.79M | 6.23M | 5.84M | 3.96M | 3.29M | 8.22M | 7.58M | 5.57M | 5.87M | 3.01M | 3.24M | 3.31M | 4.38M | 6.50M | 6.50M | 7.20M | 3.80M | 2.20M | 3.50M |
| Other Expenses | 0.00 | -1.55M | -58.00K | -49.00K | 133.00K | 126.00K | 165.00K | 1.06M | 1.95M | 3.23M | 120.00K | 138.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| Operating Expenses | 27.02M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.70M | 17.80M | 19.40M | 15.50M | 9.80M | 3.80M |
| Cost & Expenses | 27.25M | 40.80M | 33.09M | 14.75M | 16.53M | 12.81M | 6.63M | 23.72M | 36.91M | 56.85M | 65.21M | 47.74M | 27.78M | 24.32M | 28.12M | 11.11M | 35.37M | 48.68M | 30.06M | 16.58M | 10.66M | 12.20M | 8.53M | 7.64M | 12.10M | 17.00M | 18.80M | 15.00M | 9.50M | 9.30M |
| Interest Income | 825.00K | 199.00K | 17.00K | 69.00K | 170.00K | 171.00K | 21.00K | 203.00K | 119.00K | 35.00K | 150.00K | 292.00K | 220.00K | 86.00K | 47.00K | 210.00K | 2.30M | 2.85M | 714.87K | 289.59K | 213.19K | 468.48K | 539.69K | 692.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.85M | 1.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 531.00K | 0.00 | 0.00 | 0.00 | 1.03M | 0.00 | 0.00 | 434.00 | 2.98K | 6.82K | 24.63K | 42.14K | 31.67K | 13.86K | 34.06K | 470.00K | 200.00K | 970.00K | 200.00K | 800.00K | 600.00K |
| Depreciation & Amortization | 228.00K | 236.00K | 250.00K | 255.00K | 254.00K | 282.00K | 282.00K | 188.00K | 244.00K | 223.00K | 227.00K | 100.00K | 75.00K | 52.00K | 50.00K | 89.00K | 655.69K | 609.62K | 586.16K | 515.48K | 380.43K | 580.62K | 258.10K | 357.54K | 600.00K | 800.00K | 600.00K | 500.00K | 400.00K | 300.00K |
| EBITDA | -26.73M | -40.33M | -32.90M | -14.48M | -16.14M | -12.41M | -13.35M | -19.94M | -16.56M | -26.02M | -31.62M | -21.00M | -22.21M | -15.53M | 1.42M | -10.60M | -12.41M | -22.94M | -20.50M | -15.73M | -10.26M | -11.59M | 474.45K | -6.88M | 589.54K | -11.08M | 700.00K | 2.10M | -4.60M | -7.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -318.57% | -103.27% | -110.64% | -128.20% | -167.50% | -538.68% | -41.80% | -10.57% | -55.80% | -71.80% | -114.17% | -257.16% | -6.06% | -41,030.90% | -46,373.91% | 5.42% | -2,724.05% | 12.40% | -237.25% | -2.12% | 7.83% | -108.89% | -727.27% |
| Operating Income | -27.25M | -40.80M | -33.09M | -14.75M | -16.53M | -12.81M | -6.63M | -21.19M | -18.75M | -29.47M | -35.33M | -25.99M | -22.29M | -14.75M | -2.47M | -6.26M | -15.23M | -26.29M | -21.81M | -16.58M | -10.64M | -12.17M | 216.35K | -7.23M | 900.00K | -11.90M | 100.00K | 1.60M | -5.00M | -8.20M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -418.65% | -103.27% | -108.67% | -118.22% | -129.32% | -405.51% | -108.29% | -9.65% | -31.11% | -75.68% | -117.39% | -264.21% | -6.26% | -42,552.60% | -48,696.39% | 2.47% | -1,770.96% | 7.44% | -233.33% | 0.53% | 9.64% | -111.11% | -745.45% |
| Total Other Income/Expenses | -2.57M | -1.55M | -58.00K | 20.00K | 133.00K | 126.00K | -7.00M | -1.47M | 1.95M | 3.49M | 3.48M | 6.55M | 7.61M | -4.88M | 117.00K | 421.00K | 2.17M | 2.74M | 712.20K | -735.04K | 171.05K | 436.81K | 525.83K | 4.91M | 440.46K | 711.22K | 1.00M | 600.00K | -400.00K | -500.00K |
| Income Before Tax | -29.82M | -42.35M | -33.15M | -14.73M | -16.40M | -12.69M | -13.63M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -15.58M | 2.47M | -10.69M | -15.36M | -26.40M | -21.81M | -16.31M | -10.47M | -11.74M | 742.18K | -2.32M | 430.00K | -11.17M | 1.10M | 2.20M | -5.40M | -8.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -114.45% | 9.65% | -53.11% | -76.30% | -117.90% | -264.16% | -6.16% | -41,868.40% | -46,949.14% | 8.48% | -569.13% | 3.55% | -219.02% | 5.82% | 13.25% | -120.00% | -790.91% |
| Income Tax Expense | 0.00 | -475.00K | -250.00K | -69.00K | -254.00K | -126.00K | -3.05M | -1.06M | -1.95M | -3.49M | -3.48M | -6.55M | -7.61M | -3.00M | -3.01M | -2.06M | -2.17M | -2.74M | -712.20K | -264.96K | -171.05K | -101.48K | 200.00K | -176.94K | 470.00K | -730.00K | 100.00K | 500.00K | 500.00K | 200.00K |
| Net Income | -29.82M | -41.88M | -32.90M | -14.66M | -16.14M | -12.69M | -10.58M | -20.13M | -16.80M | -26.24M | -31.85M | -21.10M | -14.67M | -12.58M | 5.48M | -4.20M | -13.06M | -23.55M | -21.10M | -16.31M | -10.47M | -11.64M | 542.18K | -2.15M | 400.00K | -11.20M | 1.00M | 1.70M | -5.90M | -8.90M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -397.65% | -92.52% | -96.77% | -106.58% | -104.99% | -266.98% | -92.42% | 21.44% | -20.88% | -64.89% | -105.18% | -255.58% | -6.16% | -41,868.40% | -46,543.20% | 6.20% | -525.81% | 3.31% | -219.61% | 5.29% | 10.24% | -131.11% | -809.09% |
| EPS | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.48K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| EPS Diluted | -1.50 | -3.95 | -4.05 | -5.39 | -39.15 | -72.29 | -441.47 | -1.47K | -1.41K | -3.19K | -4.77K | -3.43K | -3.32K | -3.94K | 1.91K | -1.68K | -13.97K | -25.32K | -27.36K | -30.26K | -23.11K | -33.73K | 1.84K | -8.87K | 1.91K | -51.61K | 4.61K | 7.91K | -27.70K | -41.78K |
| Weighted Avg Shares Out | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.61K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
| Weighted Avg Shares Out (Dil) | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 13.65K | 11.89K | 8.23K | 6.67K | 6.15K | 4.42K | 3.20K | 2.58K | 2.51K | 935.00 | 930.00 | 771.00 | 539.00 | 453.00 | 345.00 | 294.00 | 242.00 | 227.00 | 217.00 | 217.00 | 215.00 | 213.00 | 213.00 |
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conduct Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conduct
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced...
Achieve Life Sciences Announces Participation in November Investor Conferences
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that...
Achieve Life Sciences To Start Cytisinicline's Trial For Nicotine E-cigarette Cessation
The FDA has signed off Achieve Life Sciences Inc's (NASDAQ: ACHV) Investigational New Drug (IND) application to investigate cytisinicline as a cessation treatment for nicotine e-cigarette users. In addition to the ongoing Phase 3 program for cytisinicline treatment in combustible cigarette cessation, the...
Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021
Seattle, WA/ Vancouver, BC , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its...
Achieve Life Sciences to Participate in Upcoming Investor Conferences
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John...
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data...
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the...
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript
Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q2 2021 Results - Earnings Call Transcript
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter...
Source: https://incomestatements.info
Category: Stock Reports